ArticleAdvanced healthcare materials2026
Injectable Supramolecular Hydrogel Encapsulating CRISPR-Engineered MSCs Drives Synergistic Neuroprotection and Functional Recovery After Traumatic Brain Injury.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Traumatic brain injury (TBI) triggers complex secondary pathologies that lack effective treatments. While mesenchymal stem cell (MSC) transplantation is promising, it is severely limited by poor cell retention and survival. To address these challenges, we engineered a combinatorial platform comprising an injectable, self-healing supramolecular gelatin hydrogel (iGel) loaded with CRISPR-SAM-engineered "Super MSCs" (SPMSCs). These cells were programmed to endogenously multiplex the activation of neuroprotective factors IL-10 and FGF21. Our results demonstrate that the biomimetic iGel niche enhances SPMSC viability and sustained factor secretion compared to 2D cultures. In a murine TBI model, iGel-encapsulated SPMSCs exerted potent immunomodulatory effects, suppressing microglial inflammation and neuronal apoptosis while restoring blood-brain barrier integrity. Furthermore, the treatment promoted angiogenesis and endogenous neurogenesis. Consequently, treated mice exhibited reduced cerebral edema and lesion volume, alongside significant improvements in sensorimotor function and spatial memory. This study establishes a versatile, gene-editing-empowered biomaterial platform that overcomes critical bottlenecks in cell therapy for central nervous system injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.